

ForPatients

by Roche

Neuromyelitis Optica Neuromyelitis optica spectrum disorder (NMOSD)

Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)

Trial Status
Completed

Trial Runs In
15 Countries

Trial Identifier
NCT02073279 SA-309JG,
2015-005431-41 BN40900

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The objectives of this study are to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic and immunogenic profiles of satralizumab in participants with NMO and NMOSD.

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT02073279 SA-309JG, 2015-005431-41 BN40900
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=18 Years & <= 74 Years

Healthy Volunteers
No
